Letter in reply

J Comp Eff Res. 2021 Dec;10(17):1267-1269. doi: 10.2217/cer-2021-0203. Epub 2021 Oct 5.

Authors

Imtiaz A Samjoo¹, Evelyn Worthington¹, Christopher Drudge¹, Melody Zhao¹, Chris Cameron², Dieter A Häring³, Dee Stoneman³, Luisa Klotz⁴, Nicholas Adlard³

Affiliations

¹ EVERSANA™, 204-3228 South Service Road, Burlington, Ontario, L7N 3H8, Canada.
² EVERSANA™, 207-275 Charlotte Street, Sydney, Nova Scotia, B1P 1C6, Canada.
³ Novartis Pharma AG, Basel, Switzerland.
⁴ Department of Neurology, University Hospital Münster, Westfälische-Wilhelms-University Münster, Münster, Germany.

PMID: 34608814
DOI: 10.2217/cer-2021-0203

No abstract available

Keywords: disease-modifying therapies; indirect treatment comparison; network meta-analysis; ofatumumab; relapsing multiple sclerosis.

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment